Canu Annie, Malbruny Brigitte, Coquemont Maëlle, Davies Todd A, Appelbaum Peter C, Leclercq Roland
UFR des Sciences Pharmaceutiques, Caen, France.
Antimicrob Agents Chemother. 2002 Jan;46(1):125-31. doi: 10.1128/AAC.46.1.125-131.2002.
Mechanisms of resistance were studied in 22 macrolide-resistant mutants selected in vitro from 5 parental strains of macrolide-susceptible Streptococcus pneumoniae by serial passage in various macrolides (T. A. Davies, B. E. Dewasse, M. R. Jacobs, and P. C. Appelbaum, Antimicrob. Agents Chemother., 44:414-417, 2000). Portions of genes encoding ribosomal proteins L22 and L4 and 23S rRNA (domains II and V) were amplified by PCR and analyzed by single-strand conformational polymorphism analysis to screen for mutations. The DNA sequences of amplicons from mutants that differed from those of parental strains by their electrophoretic migration profiles were determined. In six mutants, point mutations were detected in the L22 gene (G95D, P99Q, A93E, P91S, and G83E). The only mutant selected by telithromycin (for which the MIC increased from 0.008 to 0.25 microg/ml) contained a combination of three mutations in the L22 gene (A93E, P91S, and G83E). L22 mutations were combined with an L4 mutation (G71R) in one strain and with a 23S rRNA mutation (C2611A) in another strain. Nine other strains selected by various macrolides had A2058G (n = 1), A2058U (n = 2), A2059G (n = 1), C2610U (n = 1), and C2611U (n = 4) mutations (Escherichia coli numbering) in domain V of 23S rRNA. One mutant selected by clarithromycin and resistant to all macrolides tested (MIC, >32 microg/ml) and telithromycin (MIC, 4 microg/ml) had a single base deletion (A752) in domain II. In six remaining mutants, no mutations in L22, L4, or 23S rRNA could be detected.
通过在各种大环内酯类药物中连续传代,从5株大环内酯类敏感的肺炎链球菌亲本菌株中体外筛选出22株大环内酯类耐药突变体,对其耐药机制进行了研究(T.A.戴维斯、B.E.德瓦斯、M.R.雅各布斯和P.C.阿佩尔鲍姆,《抗菌药物与化疗》,44:414 - 417,2000年)。通过聚合酶链反应(PCR)扩增编码核糖体蛋白L22和L4以及23S rRNA(结构域II和V)的基因片段,并通过单链构象多态性分析进行分析,以筛选突变。对电泳迁移图谱与亲本菌株不同的突变体扩增子的DNA序列进行了测定。在6个突变体中,在L22基因中检测到点突变(G95D、P99Q、A93E、P91S和G83E)。唯一一株被泰利霉素筛选出的突变体(其MIC从0.008增加到0.25μg/ml)在L22基因中含有三个突变的组合(A93E、P91S和G83E)。L22突变在一株中与L4突变(G71R)组合,在另一株中与23S rRNA突变(C26A)组合。其他9株被各种大环内酯类药物筛选出的菌株在23S rRNA的结构域V中具有A2058G(n = 1)、A2058U(n = 2)、A2059G(n = 1)、C2610U(n = 1)和C2611U(n = 4)突变(大肠杆菌编号)。一株被克拉霉素筛选出且对所有测试大环内酯类药物(MIC,>32μg/ml)和泰利霉素(MIC,4μg/ml)耐药的突变体在结构域II中有一个单碱基缺失(A752)。在其余6个突变体中,未检测到L22、L4或23S rRNA的突变。